C. R. Bard, Inc. , now branded only as Bard , headquartered in Murray Hill, New Jersey, USA, is a leading multinational developer, manufacturer and marketer of medical technology in its field of vascular, urology, oncology, and surgical specialty.
In April 2017, the company has announced that it will be acquired by Becton Dickinson.
Video C. R. Bard
Overview
Bard markets its products and services worldwide to hospitals, individual health care professionals, additional treatment facilities, and alternative site facilities. S & amp; P 500 company with about 14,000 employees by 2015, Bard is probably best known for introducing the Foley catheter in 1934. In 2013, Bard started negotiations to complete nearly 30,000 lawsuits related to the vaginal trappings made by the company.
Maps C. R. Bard
History
C. R. Bard, Inc. founded in New York City by Charles R. Bard in 1907. Bard's first business involves importing Gomenol, which is used to treat discomfort in the urine. The company was officially founded in 1923, and three years later, in 1926, Charles R. Bard sold the company to John F. Willits and Edson L. Outwin for $ 18,000. Under Willits and Outwins, the company expanded its catheter business, introducing the Foley catheter in 1934 and the American Woven Catheter in 1940.
In 1948, Bard's annual sales reached $ 1 million for the first time, and the company moved its headquarters from New York City to Summit, New Jersey. In 1954, a Bard scientist, Dr. DeBakey, developed the first artery prosthesis. Three years later the company started selling Foley catheters that came in sterile packages for the first time. Bard continued to innovate in the world of catheters, rolling down the Bipolar Pacing Pacing cathode in 1958 and the first latex balloon catheter in 1960. In 1961, Bard expanded beyond the catheter, and began producing products related to cardiology, radiology, and anesthesiology.
Bard went public in 1963 and was listed on the New York Stock Exchange in 1968. The company has introduced a variety of new health care products since then. Its first net sales exceeded $ 1 billion in 1994. Around 2012, Bard acquired the Lutonix company.
On April 23, 2017, it was announced that Bard would be purchased by Becton Dickinson for $ 24 billion.
Products
Bard specializes in the manufacture of vascular, urological, oncology, and specialized surgical products.
Redemption returns illegally
In 2013, Bard agreed to pay $ 48.26 million to settle the kickback allegations filed against the company, in relation to filing false claims to Medicare. The complaint, filed in 2006, accused Bard of paying illegal bribes to doctors and consumers.
Device demands of the vaginal mesh
The vaginal mesh device is inserted into the vagina to treat incontinence or to strengthen pelvic muscles. Some women have alleged that devices are "poorly designed and contain unsafe materials for use in humans [and that] some require some surgery to remove." In 2012, the US Food and Drug Administration asked Bard and other vaginal makers to study the extent of organ damage associated with mesh devices. In 2013, Bard started negotiations to resolve nearly 30,000 legal claims related to the vaginal noose made by the company. In August 2015 it was announced that Bard had agreed to pay more than $ 200 million to complete at least 3,000 legal cases related to the device. This settlement completes about one fifth of implant-related clothing. Bard said in court that his tools were "safe and effective."
Vava cava Bard Filter
Inferior vena cava filter, or more simply, a blood clot filter, is a device percutanely placed in the vena cava to prevent blood clots from moving from the lower extremity vein to the heart or lungs, which can be fatal. On December 31, 2015, NBC News released information about their investigation of the Bard G2 series filter that had replaced the previous version, the Recovery filter. Introduced in 2002, Recovery filters were associated with 27 deaths and several hundred non-fatal problems, and "Bard's secret study commissioned showed that the Recovery filter had a higher relative risk rate for mortality, fracture filters and movement than all competitors." However, according to NBC reports, the G2 series filter is a modified version of the Recovery filter and Bard realizes that it has "the same weakness and potentially fatal" shortly after it is marketed. But instead of considering filter replacements, they remain in the market for five years. According to Bard and FDA records, at least 12 deaths and hundreds of problems have been associated with G2 series filters.
References
External links
- Official website
Source of the article : Wikipedia
0 Comments